672590.fig.005a
(a)
672590.fig.005b
(b)
672590.fig.005c
(c)
672590.fig.005d
(d)
672590.fig.005e
(e)
672590.fig.005f
(f)
Figure 5: (a) The retina in a 31-week-old untreated SDT rat. The area of stained GFAP is significantly smaller in 31-week-old untreated SDT rats than in untreated SDT rats older than 50 weeks, but there is no significant difference in retinal thickness. (b) The retina in an untreated SDT rat older than 50 weeks. The retina is thicker and the area of stained GFAP is larger compared with the normal SD rat. GFAP is strongly stained from the ILM to around the INL in the untreated SDT rats. (c) The retina in a ranirestat-treated SDT rat (0.1 mg/kg/day). The retina is thinner and the area of stained GFAP is smaller compared with the untreated SDT rat. The stained area, which appears between the ILM and around the INL in the untreated SDT rats, is suppressed. (d) The retina in a ranirestat-treated SDT rat (1.0 mg/kg/day). The effect of ranirestat (1.0 mg/kg/day) is stronger than ranirestat (0.1 mg/kg/day) on the retinal thickness and the area of stained GFAP. (e) The retina in a ranirestat-treated SDT rat (10 mg/kg/day). Although the area of stained GFAP in the ranirestat-treated SDT rat (10 mg/kg/day) is suppressed compared with the ranirestat-treated SDT rat (0.1 mg/kg/day), the difference in retinal thickness is not clear. (f) The retina in an epalrestat-treated SDT rat. Epalrestat does not suppress the retinal thickness or the area of stained GFAP. The area of GFAP is intensely stained between the ILM and around the INL.